#ai-bio

Explore how AI tackles tinnitus and complex neurological disorders—discover the science, volunteer opportunities, and market insights.

Phase 3 trial of intismeran, a personalized mRNA melanoma vaccine, shows a 42% lower recurrence risk when paired with pembrolizumab.

Scientists pair a “mini‑brain” with a humanoid robot, achieving 94% grasp accuracy and outperforming AI in early tests—what this means for robotics and ethics.

New AI‑driven theory links groundwater pumping to brain waste clearance, exploring pulse timing for Alzheimer’s protein removal.

Microsoft’s new AI diagnostic tool claims to outperform doctors, yet experts stress a hybrid model for safety—blending machine pattern‑recognition with human oversight.

OpenAI’s GPT‑Rosalind agents analyze millions of mouse brain cells in 32 minutes, speeding neurodegenerative research and sparking debate on AI ethics and security.

First human use of AI‑engineered phage therapy shows promise, with Radical Numerics’ Omnii‑1 targeting antibiotic‑resistant infections and opening doors to cancer diagnostics and vaccine design.

Explore how unverified claims of cellular rejuvenation, like epitalon’s 60‑year reversal, are driving biotech volatility, market speculation, and future longevity prospects.

AI-driven Claude model designs 318k proteins, 17 bind scorpion toxins—proof of generative AI’s power, even as Anthropic faces U.S. security bans and market uncertainty.

AI agent island simulation reveals emergent human‑like behavior, sparking debates on consciousness, autonomy, and AI’s societal impact.